Perspective Therapeutics

Perspective Therapeutics Interest Coverage

The Interest Coverage Ratio of Perspective Therapeutics (CATX) as of Oct 23, 2026 is 1.00. In the previous year, Interest Coverage Ratio was -18.23 — a change of -105.49% (higher).

Interest Coverage

1.00

YoY

-105.49%

Last updated:

Interest Coverage Ratio of Perspective Therapeutics is 2024 1.00 . Interest Coverage Ratio of Perspective Therapeutics was 2023 -18.23 . It decreases by -105.49% higher compared to the previous year.

The Perspective Therapeutics Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-210.23 USD
Jan 1, 2018
-61.17 USD
Jan 1, 2019
-175.93 USD
Jan 1, 2020
-57.93 USD
Jan 1, 2021
-28.64 USD
Jan 1, 2022
-13.20 USD
Jan 1, 2023
-18.23 USD
Jan 1, 2024
1.00 USD
The Perspective Therapeutics Interest Coverage history
YEARInterest CoverageYoY
1.00-105.49%
-18.23+38.09%
-13.20-53.92%
-28.64-50.56%
-57.93-67.07%
-175.93+187.60%
-61.17-70.90%
-210.23+520.52%
-33.88+189.09%
-11.72+68.58%
-6.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Interest Coverage Ratio of Perspective Therapeutics is 1.00 in 2024.

Interest Coverage Ratio of Perspective Therapeutics changed from -18.23 to 1.00, representing a -105.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Perspective Therapeutics

All Key Metrics — Perspective Therapeutics